Danish Hangora
Psychiatry · Joliet, ILNPI 1396146833
Payments from drug & device makers
Across 189 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$475
- Lundbeck LLC$410
- Sunovion Pharmaceuticals Inc.$407
- Alkermes, Inc.$386
- Johnson & Johnson$369
- AbbVie$280
- plus $956 from 12 others
What the payments were for
- Food & beverage$3,20498%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $475 |
| Lundbeck LLC | 30 | $410 |
| Sunovion Pharmaceuticals Inc. | 31 | $407 |
| Alkermes, Inc. | 20 | $386 |
| Johnson & Johnson | 20 | $369 |
| AbbVie(2 entities) | 13 | $280 |
| E.r. Squibb & Sons, L.L.C. | 16 | $252 |
| Neurocrine Biosciences, Inc. | 9 | $188 |
| Indivior Inc. | 6 | $129 |
| Teva Pharmaceuticals USA, Inc. | 7 | $123 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Braeburn Inc. | 1 | $26 |
| Gilead | 1 | $26 |
| Noven Therapeutics, LLC | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
How this compares
$3,284 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 85 | $228,757 |
| IngrezzaValbenazine Tosylate | 21 | $168,986 |
| Austedo XrDeutetrabenazine | 11 | $54,636 |
| VraylarCariprazine Hcl | 21 | $30,732 |
| Clozapine OdtClozapine | 12 | $10,024 |
| Lurasidone Hcl | 22 | $8,895 |
| Aripiprazole | 58 | $6,906 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,821 |
| Fluphenazine Decanoate | 52 | $5,477 |
| Ziprasidone Hcl | 33 | $4,517 |
| Fluphenazine Hcl | 50 | $4,328 |
| Quetiapine Fumarate | 121 | $2,177 |
| Hydroxyzine Hcl | 99 | $1,617 |
| Fluoxetine Hcl | 209 | $1,510 |
| Haloperidol Decanoate | 44 | $1,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $369 | $228,75785 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $188 | $168,98621 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $123 | $54,63611 claims |
| AbbVieVraylar | $280 | $30,73221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Joliet
- Cosme LozanoJoliet$687K
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.